This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 14 CIPO patents. Top assignee: Hanwha Solutions Corporation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: In Young Choi: Innovator in Diabetes Treatment
Introduction
In Young Choi is a notable inventor based in South Korea, recognized for his contributions to the field of diabetes treatment. His innovative approach focuses on improving patient compliance and reducing side effects associated with traditional insulin therapies.
Latest Patents
In Young Choi holds a patent for a composition aimed at treating diabetes. The patent, titled "Composition For Treating Diabetes, Comprising Long-Acting Insulin Analogue Conjugate And Long-Acting Insulinotropic Peptide Conjugate," outlines a method for preventing or treating diabetes through the use of long-acting insulin analogs and insulin secretion peptide conjugates. This composition is designed to enhance patient compliance by mitigating weight gain and reducing nausea, which are common side effects of insulin administration.
Career Highlights
Throughout his career, In Young Choi has focused on developing pharmaceutical compositions that alleviate the side effects experienced by pancreatic beta cells in diabetes patients. His work emphasizes the importance of reducing the dosage of insulin required through the combined use of long-acting analogs and peptide conjugates.
Collaborations
In his research endeavors, In Young Choi has collaborated with colleagues such as Jung Kuk Kim and Dae Jin Kim. Their collective efforts have contributed to advancements in diabetes treatment methodologies.
Conclusion
In Young Choi's innovative work in diabetes treatment showcases his commitment to improving patient outcomes through advanced pharmaceutical compositions. His contributions are significant in the ongoing battle against diabetes, aiming to enhance the quality of life for those affected by this condition.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
